All of the below were in the inclusion criteria for UNIFI patients EXCEPT:

A. ≥18 years of age

B. Moderate-to-severe UC diagnosis ≥3 months before screening

C. Stable doses of 5-ASA and immunomodulators were maintained from induction BL through maintenance Week 44

D. Prior TNF-antagonist therapy was discontinued ≥8 weeks and vedolizumab ≥4 months before study entry; other conventional therapies were discontinued ≥2-4 weeks before study entry

E. Oral corticosteroids were maintained at a stable dose during induction and tapered upon entering maintenance